Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2 − Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

ConclusionPalbociclib in combination with letrozole was generally well tolerated with a clinically manageable safety profile; the observed ORR supported treatment benefit in Latin American women with HR+/HER2 − ABC.Trial RegistryClinicalTrials.gov, NCT02600923.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research